SCHEMBL8266290

SCHEMBL8266290

CN1CCC(CN)(c2c(F)cccc2Cl)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39
SLC6A3 Q01959 3/20 0.38
SLC6A4 P31645 3/20 0.38
ADRA2A P08913 1/20 0.37
CYP2D6 P10635 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
TACR1 P25103 1/20 0.37
KCNH2 Q12809 1/20 0.37
OPRL1 P41146 1/20 0.37
KMT2A Q03164 2/20 0.37
HDAC4 P56524 1/20 0.37
GAA P10253 1/20 0.37
RAD52 P43351 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3324976 0.77 SLC6A4 (0.46) TAAR1SLC6A3SLC6A4TACR1KCNH2
SCHEMBL4657320 0.72 SLC6A4 (0.48) TAAR1SLC6A3SLC6A4TACR1KCNH2
SCHEMBL4656331 0.70 SLC6A3 (0.64) TAAR1SLC6A3SLC6A4TACR1KCNH2
SCHEMBL5166600 0.70 SLC6A4 (0.64) TAAR1SLC6A3SLC6A4TACR1KCNH2
SCHEMBL26922162 0.70 SLC6A3 (0.55) TAAR1SLC6A3SLC6A4
SCHEMBL4657305 0.70 SLC6A3 (0.67) SLC6A3SLC6A4
SCHEMBL4656897 0.70 SLC6A4 (0.69) SLC6A3SLC6A4
SCHEMBL468959 0.69 MAOA (0.68) TAAR1SLC6A3SLC6A4ADRA1ATACR1
Hydrochloric Acid SCHEMBL3597198 0.68 MAOA (0.66) TAAR1SLC6A3SLC6A4ADRA1ATACR1
Hydrochloric Acid SCHEMBL6805240 0.67 SLC6A3 (0.56) SLC6A3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS CTSS, CTSZ, CTSF ALDH1A1 4107/4885TAAR1 3386/4885SLC6A3 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.